Literature DB >> 20146868

Procalcitonin levels as an early marker in patients with multiple trauma under intensive care.

C Balci1, R Sivaci, G Akbulut, H S Karabekir.   

Abstract

This prospective study investigated the levels of procalcitonin (PCT) and C-reactive protein (CRP) in patients with various types and severity of multiple trauma, and their relationship to trauma-related complications. Adult multiple-trauma patients (n = 113) admitted to the intensive care unit (ICU) in the first 24 h after trauma were included. The Injury Severity Scores (ISS), and PCT and CRP levels were measured in the first 24 h (day 1), on day 7 and on the final day of their ICU stay. Survival at 30 days was recorded. Mean PCT and CRP levels were both significantly higher on day 7 compared with day 1 and the final assessment day in patients with an ISS > 20. Levels of PCT were significantly higher in cases with sepsis, severe sepsis or septic shock compared with cases who developed systemic inflammatory response syndrome (SIRS), however levels of CRP were significantly higher only in cases with severe sepsis or septic shock, but not in cases with sepsis alone. These data support the view that PCT levels may be a better indicator than CRP levels in the early diagnosis of septic complications in patients with multiple trauma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20146868     DOI: 10.1177/147323000903700606

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  12 in total

1.  Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities.

Authors:  Cristian Palmiere; Michele Mussap; Daniel Bardy; Francesco Cibecchini; Patrice Mangin
Journal:  Int J Legal Med       Date:  2012-12-22       Impact factor: 2.686

2.  Biomarkers of sepsis, a never-ending story.

Authors:  Simona Mărgărit
Journal:  Rom J Anaesth Intensive Care       Date:  2014-10

Review 3.  [Procalcitonin-based algorithm. Management of antibiotic therapy in critically ill patients].

Authors:  M Hochreiter; S Schroeder
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

4.  Diagnostic value of lipopolysaccharide-binding protein and procalcitonin for sepsis diagnosis in forensic pathology.

Authors:  Marc Augsburger; Katia Iglesias; Daniel Bardy; Patrice Mangin; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2012-10-13       Impact factor: 2.686

Review 5.  [Diagnostic markers and assessment of efficacy of antibacterial therapy].

Authors:  K-F Bodmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-05       Impact factor: 0.840

6.  Procalcitonin as a marker of sepsis and outcome in patients with neurotrauma: an observation study.

Authors:  Shuixiang Deng; Hechen Zhu; Kunlun Wang; Tongwa Cao
Journal:  BMC Anesthesiol       Date:  2013-12-15       Impact factor: 2.217

Review 7.  A Pathophysiological Insight into Sepsis and Its Correlation with Postmortem Diagnosis.

Authors:  C Pomara; I Riezzo; S Bello; D De Carlo; M Neri; E Turillazzi
Journal:  Mediators Inflamm       Date:  2016-04-27       Impact factor: 4.711

8.  Prediction of sepsis in trauma patients.

Authors:  He Jin; Zheng Liu; Ya Xiao; Xia Fan; Jun Yan; Huaping Liang
Journal:  Burns Trauma       Date:  2014-07-28

9.  The prognostic value of serum procalcitonin measurements in critically injured patients: a systematic review.

Authors:  Aziza N AlRawahi; Fatma A AlHinai; Christopher J Doig; Chad G Ball; Elijah Dixon; Zhengwen Xiao; Andrew W Kirkpatrick
Journal:  Crit Care       Date:  2019-12-03       Impact factor: 9.097

10.  Prognostic Value of Serially Estimated Serum Procalcitonin Levels in Traumatic Brain Injury Patients With or Without Extra Cranial Injury on Early In-hospital Mortality: A Longitudinal Observational Study.

Authors:  Keshav Goyal; Gaurav Singh Tomar; Kangana Sengar; Gyaninder Pal Singh; Richa Aggarwal; Kapil Dev Soni; Purva Mathur; Shweta Kedia; Hemanshu Prabhakar
Journal:  Neurocrit Care       Date:  2021-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.